European Companies Search Engine
EU funding (€5,922,396): Boosting the reduction of the environmental impact of pharmaceutical products throughout their entire life cycle. Hor2 Aug 2022 EU Research and Innovation programme "Horizon"
Overview
Text
Boosting the reduction of the environmental impact of pharmaceutical products throughout their entire life cycle.
ETERNAL aims to contribute to sustainable development of pharmaceutical manufacture, use and disposal, by using and promoting full life cycle approaches covering design, manufacture, usage, and disposal, assessing the environmental risks of not only the API and residues/metabolites, but other chemicals and by-products of the production process. This type of approach is essential to take into consideration the types of green manufacturing approach under consideration by the pharmaceutical industry, as evidenced by the range and scope of case studies being undertaken within ETERNAL. Specific application of our risk and life cycle assessment approaches to the ETERNAL case studies is a key element of the proposed work and will provide industry and policymakers with key examples of how whole life cycle assessment may be used to evaluate the changes in environmental impacts expected due to the introduction of green manufacturing processes.
Funded Companies:
| Company name | Funding amount |
| Astrazeneca UK Ltd. | ? |
| Aimplas - Asociacion de Investigacion de Materiales Plasticos y Conexas | €825,490 |
| Asociacion Espanola de Normalizacion | €91,275 |
| Asphalion SL | €151,500 |
| Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - S.p.A. | €1,091,050 |
| Enviroeye Engineeing Ltd. | €303,125 |
| Inlecom Commercial Pathways Companylimited by Guarantee | €306,875 |
| Iris Technology Solutions SL | €649,062 |
| Laboratorio Reig Jofre SA | €840,550 |
| MYBIOTECH GmbH | €423,312 |
| Universidade de Aveiro | €339,166 |
| Universitaet Fuer Bodenkultur Wien | €300,933 |
| UNIVERSITAT DES SAARLANDES | €600,058 |
Source: https://cordis.europa.eu/project/id/101057668
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Astrazeneca UK Ltd., Cambridge.
The visualizations for "Astrazeneca UK Ltd. - EU funding (€5,922,396): Boosting the reduction of the environmental impact of pharmaceutical products throughout their entire life cycle."
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
